Approval belongs to a product
Responsibility for reviewing U.S. medicines rests with the Food and Drug Administration, or FDA.
Semaglutide (Ozempic, Wegovy) has approved U.S. products, as of September 2026.
That approval does not extend to a custom-made version from a pharmacy, as of September 2026.
Source AThe form and use matter
By September 2026, semaglutide products included both tablets and injections under the Ozempic and Wegovy names.
As of September 2026, approved uses included type 2 diabetes for tirzepatide (Mounjaro) injections and long-term weight control for tirzepatide (Zepbound) injections.
Ask which product is proposed, in which form and for what health problem.
Source BA database code is not approval
The FDA drug directory identifies listed medicines with a number called an NDC; the letters stand for National Drug Code.
FDA says that an NDC or directory entry does not establish product approval, as of September 2026.
If a service offers a code as proof, ask for the actual approval record instead.
Source CRegistered is a different word
Being FDA-registered does not mean a business or its drugs have FDA approval, as of September 2026.
Approval from FDA does not cover doctors’ offices or other providers of health care, under the September 2026 position.
Use the Illinois licence record for the clinician. Ask about the medicine separately.
Source DNotes behind the answers
- Source A — FDA: Approved products and compoundingFDA compounding explanationFDA semaglutide labelBack to answer A
- Source B — FDA: Labels and product formsFDA semaglutide tablet recordFDA semaglutide labelFDA tirzepatide labelBack to answer B
- Source C — FDA: The limits of a directory codeFDA drug-code directory explanationBack to answer C
- Source D — Federal rules and FDA: Registration versus approvalFederal registration ruleFDA approval explanationBack to answer D